Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare muscle diseases through the application of adeno-associated virus (AAV) gene therapy technology. Audentes is dedicated to the development of innovative treatments based on adeno-associated virus (AAV) gene therapy technology. The company consists of a focused, experienced, and passionate team driven by the goal of improving the lives of patients. We take pride in strong, global relationships with the patient, research, and medical communities.
Genethon ; REGENX Biosciences